We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
No Agent helps landlords to manage and market their properties. No agent have created a much simpler way for landlords to manage the entire rental process which includes marketing, administration, management and 24/7 support for one fixed monthly fee.
days to go: Expired investment: £584,162
Vaboo is a customisable perks and engagement platform for the private rented sector. The platform allows clients to enhance their brand image and add value to their service through engaging communication, giveaways, and prize draws, designed to attract customers to the platform on a regular basis. Addressing core problems of the sector, Vaboo not only helps clients built their brand value, it also offers them a competitive edge in the market. By April 2019, 350+ agency branches will have brought 50,000+ renters on to the platform. Moreover, Vaboo is estimated to achieve at least a 10% market share (approx. 2000 branches) which will generate annual recurring revenues of over £4m. With the fund raised, Vaboo will focus on team expansion, product development, and sales.
days to go: Expired investment: £172,077
Using AI technology to help the elderly feel safer and more comfortable in their homes. miicare has developed wearable devices and wireless sensors to monitor body vitals. If any irregularity occurs a call will be placed to a family member, a social worker, or a 24/7 professional telecare service. This increases support for the elderly and peace of mind knowing an emergency can be easily and quickly addressed. All data is secured using blockchain encryption.
days to go: Expired investment: £321,920
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Movebubble have created a platform that connects renters with properties. Movebubble is available as a mobile app making it easy to chat and schedule viewings on the go. Their aim is to make it easier and faster to find a home to rent.
days to go: Expired investment: £833,051
Assetz Exchange (AE) is a property crowdfunding platform that endeavours to break down barriers to investing in sustainable and under-supplied Buy-To-Let sectors so that investors can create a diversified property portfolio in minutes. AE argues that Buy-To-Let has hurdles, such as capital requirements, administration burden and transaction costs making it the least preferred option for average investors. It aims to change this scenario by converting properties into micro-units, allowing investors to invest as little or as much as they like, and taking care of administrative expenses. AE has launched 12 properties so far in 2020. It also concluded the purchase of four flats in a period conversion near Sefton Park in Liverpool in January 2020 for £600,000, with a plan to sell them on for £800,000. AE envisions to originate over £20 million worth of new properties in 2021. It will use the investment to expand its network of sourcing agents, build a larger credit team, invest in marketing campaigns, and increase automation wherever possible.
days to go: Expired investment: £293,382
A technology solution for property agents to increase lead conversion rates and improve customer enquiry response times. The Triplerr app involves a recorded conversation that contains all the necessary information provided by the customer, which is sent to an agent who listens to the recording to find properties that match the customer’s criteria and can then contact the client instantly when a suitable property is found. Trippler have dubbed this 'The Voice Lead'.
days to go: Expired investment: £626,666
Net An Agent is a price comparison site for estate agents. After filling out a few details, you can instantly receive quotes from high-street and online estate agents. When you're ready, you can request a valuation and then pick which agent you'd like to market your property.
days to go: Expired investment: £6,584
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £194,100
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.

Pitch Rated

59%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,753,067
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph